← 홈

ADC

1,068개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,068개
ADCBiologicEric Thompson, M.D.DM1 and Metronomic Temozolo…Phase 1

21-day TMZ (21-day TMZ)

Glioblastoma; Glioblastoma Multiforme · Glioblastoma

#Glioblastoma#ADC#Phase1#인기#항체약물접합체+4
효능 ORR 14%임상시험 54상태 DISCONTINUED
ADCBiologicAstraZenecaPhase 2

Cediranib (Cediranib)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 26%임상시험 54상태 RECRUITING
ADCBiologicPfizerPhase 3

Docetaxel monotherapy (Docetaxel monotherapy)

Non-small Cell Carcinoma; Non-Small Cell Lung Cancer Metastatic · Non-small Cell Carcinoma

#Non-smallCellCarcinoma#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 95%임상시험 54상태 RECRUITING
ADCBiologicFondazione per la Medicina Pers…calicheamicin-based antibod…Phase 2

Ponatinib (Ponatinib)

Breast Cancer; Gastrointestinal Cancer · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 7.1%임상시험 54상태 ACTIVE
ADCBiologicSeagen Inc.deruxtecan and tucatinibPhase 1

ONT-380 (Tucatinib, Tucatinib (ONT-380))

HER2 Positive Breast Cancers · HER2

#HER2#ADC#Phase1#인기#항체약물접합체+5
효능 ORR 100%임상시험 54상태 ACTIVE
ADCBiologicQuantumLeap Healthcare Collabor…Phase 2

ABT-888 (ABT-888)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 74.1%임상시험 53상태 RECRUITING
ADCBiologicDaiichi Sankyoderuxtecan (T-DXd) in FISH-…Phase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, DS-8201a)

Colorectal Neoplasm · Malignant Neoplasm of Breast

#MalignantNeoplasmofBreast#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 74.1%임상시험 53상태 DISCONTINUED
ADCBiologicJiangsu HengRui Medicine Co., L…Phase 2

Famitinib (Famitinib)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
임상시험 53상태 RECRUITING
ADCBiologicGilead Sciencesderuxtecan (OR 4Phase 3

Idelalisib (Idelalisib)

Chronic Lymphocytic Leukaemia · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 90.9%임상시험 53상태 DISCONTINUED
ADCBiologicAdenoid Cystic Carcinoma Resear…Phase 1

IMD (Implantable Microdevice, Implantable Microdevice (IMD))

Triple Negative Breast Cancer; Breast Cancer Stage II · Triple Negative Breast Cancer

#TripleNegativeBreastCancer#ADC#Phase1#인기#항체약물접합체+3
효능 ORR 0.1%임상시험 53상태 DISCONTINUED
ADCBiologicVadim S Koshkinvedotin (BT8009) and dual-A…Phase 1

N803 (Nogapendekin Alfa Inbakicept, Nogapendekin Alfa Inbakicept (N803))

Metastatic Urothelial Carcinoma; Urothelial Carcinoma · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#ADC#Phase1#인기#항체약물접합체+5
효능 ORR 80%임상시험 53상태 DISCONTINUED
ADCBiologicCelgeneVedotinPhase 1

Romidepsin (Romidepsin)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · Cutaneous T-cell Lymphoma (CTCL)

#CutaneousT-cellLymphomaCTCL#ADC#Phase1#인기#항체약물접합체+5
효능 ORR 50%임상시험 53상태 ACTIVE
ADCBiologicKing Abdullah International Med…Vedotin Plus AVD versus ABV…Phase 2

ABVD (ABVD)

Classical Hodgkin Lymphoma; Hodgkin Lymphoma (Category) · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 96%임상시험 52상태 ACTIVE
ADCBiologicGSKinPhase 1

Belantamab (Belantamab)

Autoimmune Diseases · Autoimmune Diseases

#AutoimmuneDiseases#ADC#Phase1#인기#항체약물접합체+4
효능 ORR 40%임상시험 52상태 DISCONTINUED
ADCBiologicFudan UniversityderuxtecanPhase 2

Dalpiciclib (Dalpiciclib)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+4
임상시험 52상태 RECRUITING
ADCBiologicPfizerthatPhase 3

Inotuzumab ozogamicin (Inotuzumab ozogamicin)

Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 93.3%임상시험 52상태 RECRUITING
ADCBiologicSWOG Cancer Research NetworkVedotin, and BelinostatPhase 3

Pirtobrutinib (Pirtobrutinib)

Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 66.4%임상시험 52상태 RECRUITING
ADCBiologicRochevedotin, rituximab, cycloph…Phase 2

Polatuzumab (Polatuzumab)

Diffuse Large B Cell Lymphoma (DLBCL); High Grade B Cell Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 100%임상시험 52상태 RECRUITING
ADCBiologicSeagenvedotin-containing regimen …Phase 2

SGN-35 (brentuximab vedotin, brentuximab vedotin (SGN-35))

Hodgkin's Lymphoma · Hodgkin's Lymphoma

#HodgkinsLymphoma#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 89.5%임상시험 52상태 ACTIVE
ADCBiologicPfizerderuxtecan have preventive …Phase 2

lorlatinib (lorlatinib)

Non-Small Cell Lung Cancer · Cancer

#Cancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 75.8%임상시험 52상태 DISCONTINUED

11 / 54 페이지

← 이전다음 →